UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the **Securities Exchange Act of 1934** (Amendment No.)

Filed by a Party other than the Registrant \Box Filed by the Registrant \boxtimes

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

X Definitive Additional Materials

Soliciting Material under §240.14a-12

Omega Therapeutics, Inc. (Name of Registrant as Specified in its Charter)


(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

Х No fee required.

Fee paid previously with preliminary materials.

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.



www.virtualshareholdermeeting.com/OMGA2023

*Please check the meeting materials for any special requirements for meeting attendance.

V1.2

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

Voting Items		Board
1.	Election of Class II Directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified Nominees: 01) John Mendlein, Ph.D., J.D.	S For
	02) Mary T. Szela 03) Richard A. Young, Ph.D.	
2.	Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.	Ser 60
NOTE: Such other business as may properly come before the meeting or any adjournment thereof.		

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".

V11884-P90814